The role of early diagnosis and treatment in multiple sclerosis Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Jun 20, 2022
DOI: https://doi.org/10.24292/01.MF.0222.1
Keywords:
multiple sclerosis, diagnosis, disease modifying treatment

Main Article Content

Mariola Świderek-Matysiak
Katedra i Klinika Neurologii, Uniwersytet Medyczny w Łodzi, Uniwersytecki Szpital Kliniczny im. Norberta Barlickiego w Łodzi

Abstract

Multiple sclerosis (MS) is considered the most common acquired demyelinating disease of the central nervous system. MS is a disease affecting young people, usually between the ages of 20 and 40 years of age. The diagnosis of MS is complex, and it should take into account the medical history, family history, clinical symptoms, radioimaging and the results of laboratory tests of blood and cerebrospinal fluid. Currently, McDonald’s diagnostic criteria from 2017 allow for an early diagnosis. Introducing treatment modifying the course of MS as early as possible protects patients against subsequent relapses, radiological changes in the brain and spinal cord, but also against brain atrophy and disability.

Article Details

How to Cite
Świderek-Matysiak , M. (2022). The role of early diagnosis and treatment in multiple sclerosis. Medycyna Faktow (J EBM), 15(2(55), 122-125. https://doi.org/10.24292/01.MF.0222.1
Issue
Vol 15 No 2(55) (2022)
Section
Articles

Copyright © by Medical Education. All rights reserved.

References

1. Lublin FD, Reingold SC, Cohen JA et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014; 83: 278-86.
2. Simpson SJ, Blizzard L, Otahal P et al. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry. 2011; 82: 1132-41.
3. Kułakowska A, Bartosik-Psujek H, Hożejowski R et al. Selected aspects of the epidemiology of multiple sclerosis in Poland – a multicentre pilot study. Neurol Neurochir Pol. 2010; 44(5): 443-52. http://doi.org/10.1016/s0028-3843(14)60134-1.
4. Kapica-Topczewska K, Brola W, Fudala M et al. Prevalence of multiple sclerosis in Poland. Mult Scler Relat Disord. 2018; 21: 51-5.
5. Miller DH, Weinshenker BG, Filippi M et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Multiple Sclerosis. 2008; 14: 1157-74.
6. Stępień A. Neurologia. Vol. 3. Medical Tribune, Warszawa 2016.
7. Charil A, Yousry TA, Rovaris M et al. MRI and the diagnosis of multiple sclerosis: expanding the concept of „no better explanation”. Lancet Neurol. 2006; 5(10): 841-52.
8. Thompson AJ, Banwell BL, Barkhof F et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17: 162-73.
9. Wildner P, Stasiolek M, Matysiak M. Differential diagnosis of multiple sclerosis and other inflammatory CNS diseases. Mult Scler Relat Disord. 2020; 37: 101452. http://doi.org/10.1016/j.msard.2019.101452.
10. Montalban X, Gold R, Thompson AJ et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler J. 2018; 24(2): 96-120.
11. Ministerstwo Zdrowia. Choroby nieonkologiczne (access: 15.12.2021).
12. Giovannoni G, Butzkueven H, Dhib-Jalbut S et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016; 9(suppl 1): S5-S48.